Everything below concerns CAS Registry Number. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-12. Numbers and descriptions here follow the published literature rather than marketing material.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
== Economy == Nominal GDP growth rate: Ranked 123 of 215 (4.4 percent growth rate) Gross domestic product 2013: Ranked 30 of 192 (US$387 billion). Economic Misery Index 2015: Bloomberg News ranked Thailand number one of fifty-one nations as the happiest economy, largely due to its low inflation and unemployment. Quality of Life Index: Ranked 42 of 111 countries. Index of Economic Freedom 2022: The Heritage Foundation ranked Thailand 70 of 177 countries. A.T. Kearney/Foreign Policy Magazine: Globalization Index 2005. Ranked 46 of 62 countries World Talent Ranking, 2014: The International Institute for Management Development (IMD) assesses "the ability of countries to develop, attract and retain talent to sustain the talent pool available for enterprises operating in those economies." Ranked 34 of 60 countries. Global Talent Competitiveness Index, 2014. Thailand ranks 61 of 93 nations in this analysis of growing local talent or attracting talent from abroad.
=== Mitochondrial genetics === Mitochondrial genetics concerns the diagnosis and management of mitochondrial disorders, which have a molecular basis but often result in biochemical abnormalities due to deficient energy production. There exists some overlap between medical genetic diagnostic laboratories and molecular pathology. In the UK, the NHS Highly Specialised Service for Rare Mitochondrial Disorders offers diagnostic testing for patients. Based in laboratories in Newcastle upon Tyne , Oxford and London which are integrated within the NHS Genomic Medicine Service (GMS).
=== Ion funnel === Ion funnels are RF devices which have been used for decades to focus ion currents into narrow beams. In PTR-MS they have been introduced in 2012 by Barber et al. when they presented a PTR-MS setup with a PTR reaction region incorporating an ion funnel. Although the focusing properties of the ion funnel improved the sensitivity of the setup by a factor of >200 (compared to operating in DC only mode, i.e. with the ion funnel turned off) for some compounds, the sensitivities of other compounds were only improved by a factor of <10. That is, because of the highly compound dependent instrumental response one of the main advantages of PTR-MS, namely that concentration values can be directly calculated, is lost and a calibration measurement is needed for each analyte of interest. Furthermore, with this approach unusual fragmentation of analytes has been observed which complicates interpretation of measurement results and comparison between different types of instruments even more. A different concept has been introduced by the company IONICON Analytik GmbH. (Innsbruck, AT) where the ion funnel is not predominantly part of the reaction region but mainly for focusing the ions into the transfer region to the TOF mass spectrometer. In combination with the above-mentioned method of controlling the ion chemistry this enables a considerable increase in sensitivity and thus also an improvement of the detection limit, while keeping the ion chemistry well-defined and thus avoiding problems with quantification and interpretation of the results.
Sources: en.wikipedia.org
== External links == The MEROPS online database for peptidases and their inhibitors: I35.001 Overview of all the structural information available in the PDB for UniProt: P01033 (Metalloproteinase inhibitor 1) at the PDBe-KB.
The secondary stage occurs months to two years later (but usually 1–2 months later), and may thus begin when the mother wound has not yet healed. It happens when the bacterium spreads in the blood and lymph. It begins as multiple, pinhead-like papules; these initial lesions grow and change in appearance and may last weeks before healing, with or without scarring. Secondary yaws typically shows widespread skin lesions that vary in appearance, including "crab yaws" (areas of skin of abnormal color) on the palms of the hands and soles of the feet (named for the crab-like gait they cause people with painful soles to assume). These may show desquamation. These secondary lesions frequently ulcerate and are then highly infectious, but heal after 6 months or more. Secondary yaws affects the skin and bones. The most common bone-related problem is periostitis, an inflammation around the bone, which often occurs in the bones of the fingers and the long bones of the lower arms and legs, causing swollen fingers and limbs. This causes pain at night and thickening of the affected bones (periostitis). About 75% of infected children surveyed in Papua New Guinea reported joint pain. Swollen lymph nodes, fever, and malaise are also common. A latent infection develops after primary and secondary yaws (and possibly, in some cases, without these phases). Within five years (rarely, within ten years), it can relapse and become active again, causing further secondary lesions, which may infect others. These relapse lesions are most commonly found around the armpits, mouth, and anus.
=== Music === The word "Water" has been used by many Florida based rappers as a sort of catchphrase or adlib. Rappers who have done this include BLP Kosher and Ski Mask the Slump God. To go even further some rappers have made whole songs dedicated to the water in Florida, such as the 2023 Danny Towers song "Florida Water".
David Andrew Sinclair (born June 26, 1969) is an Australian-American biologist and academic known for his research on aging and epigenetics. Sinclair is a professor of genetics at Harvard Medical School and the founding director of the Paul F. Glenn Laboratories for the Biological Mechanisms of Aging at Harvard. He is the co-author of Lifespan: Why We Age – and Why We Don't Have To.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.